ALNY

Alnylam Pharmaceuticals has achieved solid profitability with Q2 2026 net income of $164.5 million and revenue growth of 67% year-over-year, yet its stock has plunged over 40% this year. The decline is attributed to a revenue guidance cut for its drug Amvuttra due to demand normalization and investor concerns about a rival drug's clinical setback. However, Wall Street remains bullish with 19 of 23 analysts recommending a buy, citing the company's strong financials, robust product growth, and promising pipeline.

Alnylam Pharmaceuticals faces a securities fraud investigation following a significant stock price decline. On July 30, 2026, the company lowered its TTR product sales guidance by approximately $200 million due to slower-than-expected market adoption in the ATTR-CM market after initial pent-up demand was satisfied. The announcement triggered a 28.31% stock price drop, prompting a class action investigation by Glancy Prongay Wolke & Rotter LLP on behalf of affected shareholders.

The Law Offices of Frank R. Cruz is investigating Alnylam Pharmaceuticals for potential federal securities law violations. On July 30, 2026, Alnylam lowered its full-year 2026 TTR product sales guidance by approximately $200 million due to slower-than-expected growth in the ATTR-CM market after initial pent-up demand was satisfied. The announcement triggered a sharp 28.31% stock price decline, causing investor losses.